Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome
about
Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitorsMolecular Mechanisms and Metabolomics of Natural Polyphenols Interfering with Breast Cancer MetastasisMicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancerTissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.Methylation of TIMP3 in esophageal squamous cell carcinomaGrowth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets.Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.Differential impact of flavonoids on redox modulation, bioenergetics and cell signalling in normal and tumor cells: a comprehensive review.Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.Hydrogen peroxide regulates angiogenesis-related factors in tumor cells.Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.
P2860
Q26830522-39B54297-450B-4F35-B08B-E35DCB7C5B25Q28076953-D8E7B8A3-A3ED-4873-B517-10A915B5B1B9Q33784804-C222E3A3-BBE5-4E4C-856F-0F05E07E45DCQ34626693-7484B6CD-334E-408B-90F7-225071E33DF2Q34995520-3EDF32D7-BC86-407A-B86C-81650B14624DQ35152040-A6DCA24D-1144-42E7-B962-073459A1DFFCQ37174136-8DE5118D-82F0-4881-9ACD-3F4A944AEA16Q37179767-39E0103D-B774-4BC0-8537-30E0EA7C19F6Q37351433-1674E168-28F2-4C62-86F3-55B60F0FDD95Q38616035-C128031E-96D2-4774-9EFE-00AA18114E6AQ39028680-54A19D7E-A7D7-4F3E-95BA-31BD391C13F5Q39258051-5E6BFC53-A979-434A-B3E4-73A434A2AD8BQ42252255-DADB8591-66BE-47BE-9F95-93765BCE7EE2Q42315758-08537026-51F6-4C72-885C-65133A7EAE25Q51185139-182424CB-E63C-40C2-B6B3-7B79784EF88BQ54356219-E464DE14-07DD-4696-9409-E59112894BCA
P2860
Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Expression of tissue inhibitor ...... phenotype and clinical outcome
@ast
Expression of tissue inhibitor ...... phenotype and clinical outcome
@en
type
label
Expression of tissue inhibitor ...... phenotype and clinical outcome
@ast
Expression of tissue inhibitor ...... phenotype and clinical outcome
@en
prefLabel
Expression of tissue inhibitor ...... phenotype and clinical outcome
@ast
Expression of tissue inhibitor ...... phenotype and clinical outcome
@en
P2093
P2860
P356
P1476
Expression of tissue inhibitor ...... phenotype and clinical outcome
@en
P2093
Antonios Keramopoulos
Christina Magkou
Eleni Mylona
George Agrogiannis
Ioanna Giannopoulou
Lydia Nakopoulou
Sofia Markaki
P2860
P2888
P356
10.1186/BCR1607
P577
2006-01-01T00:00:00Z
P5875
P6179
1028695997